Market research
ICPT Intercept Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 795M
- P/E ratio
- Not available
- Analyst target
- 19
- Dividend yield
- 0.0%
- Beta
- 0.88
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US45845P1084
- Market cap
- 795M
- P/E ratio
- Not available
- Analyst target
- 19
- Dividend yield
- 0.0%
- Beta
- 0.88
About
About Intercept Pharmaceuticals Inc
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ICPT discussion.
5 years, 4 months ago
Intercept Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 29.2% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.6.
Intercept Pharmaceuticals, Inc's total revenue rose by 16.5% to $83M since the same quarter in the previous year.
Its net income has increased by 46.9% to $-52M since the same quarter in the previous year.
Finally, its free cash flow grew by 70.5% to $-18M since the same quarter in the previous year.
Based on the above factors, Intercept Pharmaceuticals, Inc gets an overall score of 4/5.